[Ip-health] News: Sourcejuice.com- The rapid development of India's pharmaceutical industry will take time quantum leap in yield potential

Marine Avrillon Marine at haieurope.org
Thu Oct 28 03:36:12 PDT 2010

In recent years, the rapid rise of the Indian pharmaceutical industry in
the international pharmaceutical market, accounted for an important
seat. So to the good prospects for the Indian pharmaceutical industry
also faces what's confusing it? 


Yield potential 


According to medical information giant IMS Health (IMS) market research
report released by the Indian pharmaceutical industry has become the
world's four fastest growing markets in the world pharmaceutical
industry. In the past few years, the Indian pharmaceutical industry,
sustained economic growth, health care reform and the development of the
relevant patent law, has aroused great interest in the global
pharmaceutical business. 


In the past 5 years, the Indian domestic pharmaceutical market compound
annual growth rate of about 12% by 2015, the Indian pharmaceutical
market compound annual growth rate will reach 9.5%. India is also
increasing the income of the rural population, drug distribution
networks become more perfect, contributed to the pharmaceutical market
in rural India with high growth potential. By 2011, India's population
over the age of 67 is expected to reach 6700 million people in this age
group spending on drugs will increase 3 to 4 times, no doubt also
indicates that the Indian pharmaceutical industry has a potential engine
of growth. At the same time, the positive awareness of the patent
medicine Indian pharmaceutical companies make the investment in research
and development continues to grow. Data show that, as of the end of
2010, India's patent medicine market share will reach 10%. 


Analysis shows that consumers spend on health care and medicines
increase was mainly due to increased affordability, disease patterns,
transformation and modest health care reform. Indian family health care
budget in 2005 was 7%, to 13% in 2025. FICCI-Ernst & Young study
predicted the company to India, said: By 2015, India's domestic
pharmaceutical market will reach 200 billion dollars in shares. 


India's pharmaceutical industry, the Commerce Department estimated that
annual investment in India is about 6.31 billion U.S. dollars. 


Due to the current low level of R & D investment in 2012, the Indian
pharmaceutical related industries, 25 billion dollars will be growth


By 2015, the Indian patent medicine will be given 10% share of the
pharmaceutical industry, 20 billion dollars. 


India's generic pharmaceutical industry continued to rule the market. In
2011-2013, there will be 61 U.S. 800 billion dollars the value of drug
patents expire, the Indian pharmaceutical industry through the
production of generic drugs already prepared a large profit. 


By 2015, specialist treatment will occupy 45% of pharmaceutical market
share. And lifestyle-related diseases will increase, especially in
metabolic diseases such as diabetes and obesity, and coronary heart
disease, hypertension, cardiovascular disease, psychiatric and
neurological tumor, the treatment of these diseases will have a
considerable growth. 


Although the future of the specialist treatment of disease trends, but
the general treatment of the current pharmaceutical industry in India
still occupies an important position, primarily the incidence of common
diseases and treatment gap exists between the rate, such as anemia,
diarrhea, gastrointestinal and respiratory disease, acute pain,
infection, incidence of these diseases is also very large population. As
people's income increases, cost of treatment of acute illness in general
is also very impressive. 


Take time to leap 


Indian pharmaceutical companies have been deliberately into the
development of new drugs. Recently, the Mumbai Piramal, a pharmaceutical
company to its generic drugs business is sold for 3.7 billion U.S.
pharmaceutical company Abbott, is said to lead India in the 2012 wave of
drug development. 


Not everyone is convinced that India's pharmaceutical industry, the
strength of pioneering research. A meeting in August, the Indian Council
of Medical Research Director-General Dr VMKatoch said: "Indian
Pharmaceutical Industry has a great dream, but time is not ripe." 


To help the Indian generic drug production and distribution capacity to
quickly become the world's third largest pharmaceutical industrial
countries, but also by the U.S. Food and Drug Administration (FDA)
approved the largest U.S. manufacturing facilities outside the country.
Meanwhile, India in the drug development process more and more
interested in clinical trials. 


Today, as companies like Piramal India sterile injection manufacturer
JubilantOrganosys, small molecule and peptide drug development company
Syngene gene Aurigene I think the company best-selling drug in the new
market share. 


However, many industry experts say India's pharmaceutical research and
development to cutting-edge changes there are also some problems. In
developed countries, universities play a key drug development role. In
India, the science department of the University infrastructure is poor,
the role is extremely limited. Even places with better conditions,
academic researchers and laboratory staff is also very little


In addition, India is simply the work of some members of contract
research, which means the current Indian pharmaceutical drug development
company into the upper reaches of the remaining difficult. But Dr.
Katoch said that the government will help the Indian pharmaceutical
companies to overcome their difficulties. 


In short, the Indian pharmaceutical industry grew rapidly over the past
10 years, in the next 10 years, also has strong growth potential.
However, the growth potential of India's pharmaceutical industry
realized the need to join the government and the pharmaceutical industry
through a continuous, gradual co-operation to complete. 





More information about the Ip-health mailing list